Cystic Fibrosis Market, By Drug Class (Mucolytic {Mucoactive Drugs} and Bronchodilators, CFTR modulators, Antibiotics, Pancreatic Enzyme Replacement Therapy {PERT}), By Route of Administration (Oral, Inhalation), By Form (Powder, Liquid, Capsule, Tablet), By Distribution Channel (Offline {Hospital Pharmacies, Retail Pharmacies},Online Pharmacies ), by Region (United States, Canada, Mexico, France, The UK, Spain, Germany, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Brazil, Argentina, Rest of Latin America, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) — Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019–2027

Report ID :AMI-520 | Category : Healthcare | Published Date : March, 2020 | Pages : 402 | Format :PDF

Market Overview/Industry Trends

In terms of revenue, the global cystic fibrosis market was estimated to be US$ 9,839.9 Mn in 2019 and is expected to reach US$ 17,656.8 Mn by 2027 growing at a CAGR of 7.6% over the forecast period.

Cystic fibrosis is a hereditary disease that affects a body’s secretory glands including lungs, pancreas, liver and intestines. The most common organ affected by cystic fibrosis is lungs. Cystic fibrosis leads to irregular secretions leading to accumulation of mucus which does not result in proper functioning of an affected organ. Cystic fibrosis diagnosis requires a physical therapy that helps remove the mucus and use antibiotics and enzymes to combat an organ infection. Cystic fibrosis is caused by gene mutation necessary for the transmembrane conductance regulator (CFTR) for the protein cystic fibrosis. Sweat, mucus, and body secretions are regulated by CFTR. Cystic fibrosis is identified by conducting sweat and genetic tests. Physical therapy is used to treat cystic fibrosis patients including reduction in the production of mucus among others to combat against organ infections. Furthermore, cystic fibrosis therapy involves the use of medications such as Pulmozyme, a drug manufactured by Roche Holding AG, a pharmaceutical company based in Switzerland and Kalydeco, a drug manufactured by Vertex Pharmaceuticals Incorporated, among others. The medication for cystic fibrosis can be administered to a patient by various routes such as oral and inhalation is increasing the demand in global cystic fibrosis market.  

Many new drug developments with improved effectiveness, and outcomes are expected to offer good opportunities for the market for cystic fibrosis treatment. To quote for instance, the United States, food and drug administration (FDA) has approved a new drug “Trikafta” from Vertex Pharmaceuticals, Inc., to treat cystic fibrosis patient. Trikafta is first triple combination therapy drug containing three CFTR modulators and they are Elexacaftor, tezacaftor, and ivacaftor.  The drug has passed through the two clinical trials, treating 510 cystic fibrosis patients. In the research it is found that, patient who took “Trikafta” has improved their breathing by 13.8% compared who took another medicine placebo and in second trail 10% improvement in breathing has been recorded thus leading to increase in demand for global cystic fibrosis market.

Furthermore, due to their large population base and growing economy, emerging markets hold great potential for growth of the demand for cystic fibrosis therapy. Some of the major trends found in the market for cystic fibrosis therapeutics include the introduction of various drugs into the field of antibiotics. Moreover, companies are involved in the research and development of new drugs for cystic fibrosis treatment. For instance, Novartis, a Swiss Pharmaceutical company, got an approval from the United States Food and Drug Administration (FDA), for a formulation for an antibiotic which fights the bacterial infection in the patients affected with cystic fibrosis thus leading to increasing the demand in global cystic fibrosis market. Nevertheless, high cost of treatment, increased complexity of the condition restricts the market for cystic fibrosis. The study analyzes the market in terms of revenue across all the major regions, which has been further bifurcated into countries.

Cystic Fibrosis Market Revenue & Forecast, (US$ Million), 2015–2027

Drug Class Outlook

In 2018, the CFTR modulators segment dominated the global cystic fibrosis therapeutics market and holds a major share of the global market. The segment is expected to maintain its dominance throughout the forecast period due to rise in approval of CFTR modulators based medicines by several countries food and drug administration body in the recent years. Moreover, the segment is projected to register the fastest growth during the forecasted period. This is due to rise in usage of these drugs for the treatment of cystic fibrosis. On the other hand antibiotics drug type is expected to register the fastest market growth over the forecast period that attributed to increase use of antibiotics regularly as a chronic, suppressive therapy against persistent bacterial infection thus leading to increasing the demand in global cystic fibrosis market.

Route of Administration Outlook

Based on the route of administration, the market is segmented into oral and inhaled. Oral route has accounted for holding the majority of market share due to the advantages associated with its administration such as convenience and ease of consumption without the help of a healthcare professional. In addition, growing awareness in emerging economies about the benefits of oral drugs, which include CFTR modulators and pancreatic enzyme supplements is one of the crucial factors anticipated to propel the demand for these drugs thus increasing the demand in global cystic fibrosis market.

There are some approved therapeutics that are administered orally. CFTR modulators are one of the oral therapeutics and that includes medicine drug brands including Kalydeco, Orkambi among others. The pancreatic enzyme supplements are another method of oral therapeutic and that offers drugs, such as Creon/Zenpep, PERTZYE, Ultresa, and Viokace. Due to high commercial availability and huge demand for these drugs to treat cystic fibrosis are expected to drive the oral drug segment. In 2017 according to the U.S. patient registry, hypertonic saline was prescribed to 28.3 % children falling under the age group of zero to three years and 46.9 % of children in the age group of three to five years. Increasing prevalence of cystic fibrosis among newborn babies is one of the key factors responsible for the growing demand for oral drug formulation this leading to increasing the demand in global cystic fibrosis market.  

By Form Outlook

Based on the form, the market is segmented into powder, liquid, capsule, and tablet. The liquid form is dominating the respective segment due to its application. The liquid form is used in both route of administration, for instance, liquid syrups intake is by oral route and other form of liquid medicine through the inhaler and nebulize mask thus increasing the demand in global cystic fibrosis market.

On other hand the tablet form is expected to register the fastest market growth over the forecast period that attributed to the easy way of intakes and easy availability into the market thus leading to increasing the demand in global cystic fibrosis market.

Distribution Channel Outlook

In terms of distribution channel, the market is segmented into offline distribution channel and online distribution channel. Offline distribution channel is further bifurcated in hospital pharmacies and retail pharmacies. The offline distribution channel segment has registered the highest market share due to the conventional supply chain management establishment and expected to lead revenue table by the forecasted period. However, the online distribution channel is expected to propel the market with significant CAGR due to the rising trend of e-pharmacy and convenience factor for consumers thus leading to increasing the demand in global cystic fibrosis market.

Regional Outlook

Geographically, the global cystic fibrosis market is bifurcated into North America, Europe, Asia Pacific, and the Middle East & Africa. North America is one of the majorly affected region by the cystic fibrosis disease among other regions. The United States is among the countries that has highest number of cystic fibrosis cases. According to the Cystic Fibrosis Trust, more than 30,000 are found in the US having cystic fibrosis disease. Approximately, 1,000 new cases of cystic fibrosis are diagnosed every year and more than half of the cystic fibrosis population is age 18 years or more. Other significant factors that are attributing growth to North America market is the availability of advanced medical facilities, overall technological advancement, presence of strong economic conditions, and the presence of many key market players, of the medical sector thus leading to increasing the demand in global cystic fibrosis market.

Europe is the second-largest regional market, as the region shares the second-largest patient population. Importantly the advanced medical facilities are available in most of European countries. In the given region, the strongest countries that majorly drive the market are France, Germany, and the UK. The Asia Pacific is a comparatively smaller market for cystic fibrosis in comparison to North America and Europe due to limited information and healthcare facilities. However, countries that have the potential to become lucrative markets by improving their healthcare facilities are China, India, and Japan. The Middle East and Africa region has the smallest market share due to the majority of under developed countries among the region and low standards of medical facilities thus leading to increasing the demand in global cystic fibrosis market.

Competitive Landscape

The report provides both qualitative and quantitative research of cystic fibrosis market as well as provides comprehensive insights and development methods adopted by the prominent market players. Some of the key market participants in the cystic fibrosis market are AbbVie Inc, Aradigm Corporation, Celtaxsys Aus Pty Limited, CHIESI Farmaceutici S.p.A., Demegen, Inc.  Digestive Care, Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlaxoSmithKline Plc., Grifols, S.A., Mylan N.V., Pharmaxis Ltd., Polydex Pharmaceuticals Limited, PTC Therapeutics, Vertex Pharmaceuticals Incorporated  amongst others. Major market players are offering their solution with new technologies and integrated point of sales solutions to retailers, pharmacies, hospitals, etc. An increase in the incidence of cystic fibrosis has resulted in the need for modern and innovative medical therapies. This has led to an increase in the number of pipeline drugs on the market, which in the forecast period is projected to provide remunerative incentives for business expansion. For each company, the report studies their global presence, competitors, and product offerings, among others.

Global Cystic Fibrosis Market:

  • By Drugs Class
    • CFTR Modulators
    • Mucolytics (Mucoactive Drugs) and Bronchodilators
    • Antibiotics
    • Pancreatic Enzyme Replacement Therapy (PERT)
  • By Route of Administration
    • Oral
    • Inhaled drugs
  • By Form
    • Powder
    • Liquid
    • Capsule
    • Tablet
  • By Distribution Channel
    • Offline Pharmacies
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
      • Rest of North America
    • Europe
      • France
      • The UK
      • Spain
      • Germany
      • Italy
      • Nordic Countries
        • Denmark
        • Finland
        • Iceland
        • Sweden
        • Norway
      • Benelux Union
        • Belgium
        • The Netherlands
        • Luxembourg
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • New Zealand
      • Australia
      • South Korea
      • Southeast Asia
        • Indonesia
        • Thailand
        • Malaysia
        • Singapore
        • Rest of Southeast Asia
      • Rest of Asia Pacific
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • Egypt
      • Kuwait
      • South Africa
      • Rest of Middle East & Africa
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America

1.    Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2013 - 2017

1.2.2. Base Year: 2018

1.2.3. Forecast Years: 2019 – 2027

2.    Key Target Audiences

3.    Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4.    Recommendations and Insights from AMI’s Perspective**

5.    Holistic Overview of Cystic Fibrosis Therapeutics Market

6.    Market Synopsis:  Cystic Fibrosis Therapeutics Market

7.    Cystic Fibrosis Therapeutics Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.2.4. Challenges

7.3. Trends in Cystic Fibrosis Therapeutics Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Cystic Fibrosis Therapeutics Market

7.6. Porter’s Five Force Analysis

8.    Global Cystic Fibrosis Therapeutics Market Analysis and Forecasts, 2019 – 2027

8.1. Overview

8.1.1. Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn)

8.2. Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

8.2.1. CFTR Modulators

8.2.1.1.    Definition

8.2.1.2.    Market Estimation and Penetration, 2013 – 2018

8.2.1.3.    Market Forecast, 2019 – 2027

8.2.1.4.    Compound Annual Growth Rate (CAGR)

8.2.1.5.    Regional Bifurcation

8.2.1.5.1. North America

8.2.1.5.1.1. Market Estimation, 2013 – 2018

8.2.1.5.1.2. Market Forecast, 2019 – 2027

8.2.1.5.2. Europe

8.2.1.5.2.1. Market Estimation, 2013 – 2018

8.2.1.5.2.2. Market Forecast, 2019 – 2027

8.2.1.5.3. Asia Pacific

8.2.1.5.3.1. Market Estimation, 2013 – 2018

8.2.1.5.3.2. Market Forecast, 2019 – 2027

8.2.1.5.4. Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2013 – 2018

8.2.1.5.4.2. Market Forecast, 2019 – 2027

8.2.1.5.5. Latin America

8.2.1.5.5.1. Market Estimation, 2013 – 2018

8.2.1.5.5.2. Market Forecast, 2019 – 2027

8.2.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

8.2.2.1.    Definition

8.2.2.2.    Market Estimation and Penetration, 2013 – 2018

8.2.2.3.    Market Forecast, 2019 – 2027

8.2.2.4.    Compound Annual Growth Rate (CAGR)

8.2.2.5.    Regional Bifurcation

8.2.2.5.1. North America

8.2.2.5.1.1. Market Estimation, 2013 – 2018

8.2.2.5.1.2. Market Forecast, 2019 – 2027

8.2.2.5.2. Europe

8.2.2.5.2.1. Market Estimation, 2013 – 2018

8.2.2.5.2.2. Market Forecast, 2019 – 2027

8.2.2.5.3. Asia Pacific

8.2.2.5.3.1. Market Estimation, 2013 – 2018

8.2.2.5.3.2. Market Forecast, 2019 – 2027

8.2.2.5.4. Middle East and Africa

8.2.2.5.4.1. Market Estimation, 2013 – 2018

8.2.2.5.4.2. Market Forecast, 2019 – 2027

8.2.2.5.5. Latin America

8.2.2.5.5.1. Market Estimation, 2013 – 2018

8.2.2.5.5.2. Market Forecast, 2019 – 2027

8.2.3. Antibiotics

8.2.3.1.    Definition

8.2.3.2.    Market Estimation and Penetration, 2013 – 2018

8.2.3.3.    Market Forecast, 2019 – 2027

8.2.3.4.    Compound Annual Growth Rate (CAGR)

8.2.3.5.    Regional Bifurcation

8.2.3.5.1. North America

8.2.3.5.1.1. Market Estimation, 2013 – 2018

8.2.3.5.1.2. Market Forecast, 2019 – 2027

8.2.3.5.2. Europe

8.2.3.5.2.1. Market Estimation, 2013 – 2018

8.2.3.5.2.2. Market Forecast, 2019 – 2027

8.2.3.5.3. Asia Pacific

8.2.3.5.3.1. Market Estimation, 2013 – 2018

8.2.3.5.3.2. Market Forecast, 2019 – 2027

8.2.3.5.4. Middle East and Africa

8.2.3.5.4.1. Market Estimation, 2013 – 2018

8.2.3.5.4.2. Market Forecast, 2019 – 2027

8.2.3.5.5. Latin America

8.2.3.5.5.1. Market Estimation, 2013 – 2018

8.2.3.5.5.2. Market Forecast, 2019 – 2027

8.2.4. Pancreatic Enzyme Replacement Therapy (PERT)

8.2.4.1.    Definition

8.2.4.2.    Market Estimation and Penetration, 2013 – 2018

8.2.4.3.    Market Forecast, 2019 – 2027

8.2.4.4.    Compound Annual Growth Rate (CAGR)

8.2.4.5.    Regional Bifurcation

8.2.4.5.1. North America

8.2.4.5.1.1. Market Estimation, 2013 – 2018

8.2.4.5.1.2. Market Forecast, 2019 – 2027

8.2.4.5.2. Europe

8.2.4.5.2.1. Market Estimation, 2013 – 2018

8.2.4.5.2.2. Market Forecast, 2019 – 2027

8.2.4.5.3. Asia Pacific

8.2.4.5.3.1. Market Estimation, 2013 – 2018

8.2.4.5.3.2. Market Forecast, 2019 – 2027

8.2.4.5.4. Middle East and Africa

8.2.4.5.4.1. Market Estimation, 2013 – 2018

8.2.4.5.4.2. Market Forecast, 2019 – 2027

8.2.4.5.5. Latin America

8.2.4.5.5.1. Market Estimation, 2013 – 2018

8.2.4.5.5.2. Market Forecast, 2019 – 2027

8.3. Key Segment for Channeling Investments

8.3.1. By Drugs Class

9.    Global Cystic Fibrosis Therapeutics Market Analysis and Forecasts, 2019 – 2027

9.1. Overview

9.2. Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

9.2.1. Oral

9.2.1.1.    Definition

9.2.1.2.    Market Estimation and Penetration, 2013 – 2018

9.2.1.3.    Market Forecast, 2019 – 2027

9.2.1.4.    Compound Annual Growth Rate (CAGR)

9.2.1.5.    Regional Bifurcation

9.2.1.5.1. North America

9.2.1.5.1.1. Market Estimation, 2013 – 2018

9.2.1.5.1.2. Market Forecast, 2019 – 2027

9.2.1.5.2. Europe

9.2.1.5.2.1. Market Estimation, 2013 – 2018

9.2.1.5.2.2. Market Forecast, 2019 – 2027

9.2.1.5.3. Asia Pacific

9.2.1.5.3.1. Market Estimation, 2013 – 2018

9.2.1.5.3.2. Market Forecast, 2019 – 2027

9.2.1.5.4. Middle East and Africa

9.2.1.5.4.1. Market Estimation, 2013 – 2018

9.2.1.5.4.2. Market Forecast, 2019 – 2027

9.2.1.5.5. Latin America

9.2.1.5.5.1. Market Estimation, 2013 – 2018

9.2.1.5.5.2. Market Forecast, 2019 – 2027

9.2.2. Inhalation

9.2.2.1.    Definition

9.2.2.2.    Market Estimation and Penetration, 2013 – 2018

9.2.2.3.    Market Forecast, 2019 – 2027

9.2.2.4.    Compound Annual Growth Rate (CAGR)

9.2.2.5.    Regional Bifurcation

9.2.2.5.1. North America

9.2.2.5.1.1. Market Estimation, 2013 – 2018

9.2.2.5.1.2. Market Forecast, 2019 – 2027

9.2.2.5.2. Europe

9.2.2.5.2.1. Market Estimation, 2013 – 2018

9.2.2.5.2.2. Market Forecast, 2019 – 2027

9.2.2.5.3. Asia Pacific

9.2.2.5.3.1. Market Estimation, 2013 – 2018

9.2.2.5.3.2. Market Forecast, 2019 – 2027

9.2.2.5.4. Middle East and Africa

9.2.2.5.4.1. Market Estimation, 2013 – 2018

9.2.2.5.4.2. Market Forecast, 2019 – 2027

9.2.2.5.5. Latin America

9.2.2.5.5.1. Market Estimation, 2013 – 2018

9.2.2.5.5.2. Market Forecast, 2019 – 2027

9.3. Key Segment for Channeling Investments

9.3.1. By Route of Administration

10. Global Cystic Fibrosis Therapeutics Market Analysis and Forecasts, 2019 – 2027

10.1. Overview

10.2. Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

10.2.1. Powder

10.2.1.1.  Definition

10.2.1.2.  Market Estimation and Penetration, 2013 – 2018

10.2.1.3.  Market Forecast, 2019 – 2027

10.2.1.4.  Compound Annual Growth Rate (CAGR)

10.2.1.5.  Regional Bifurcation

10.2.1.5.1. North America

10.2.1.5.1.1. Market Estimation, 2013 – 2018

10.2.1.5.1.2. Market Forecast, 2019 – 2027

10.2.1.5.2. Europe

10.2.1.5.2.1. Market Estimation, 2013 – 2018

10.2.1.5.2.2. Market Forecast, 2019 – 2027

10.2.1.5.3. Asia Pacific

10.2.1.5.3.1. Market Estimation, 2013 – 2018

10.2.1.5.3.2. Market Forecast, 2019 – 2027

10.2.1.5.4. Middle East and Africa

10.2.1.5.4.1. Market Estimation, 2013 – 2018

10.2.1.5.4.2. Market Forecast, 2019 – 2027

10.2.1.5.5. Latin America

10.2.1.5.5.1. Market Estimation, 2013 – 2018

10.2.1.5.5.2. Market Forecast, 2019 – 2027

10.2.2. Liquid

10.2.2.1.  Definition

10.2.2.2.  Market Estimation and Penetration, 2013 – 2018

10.2.2.3.  Market Forecast, 2019 – 2027

10.2.2.4.  Compound Annual Growth Rate (CAGR)

10.2.2.5.  Regional Bifurcation

10.2.2.5.1. North America

10.2.2.5.1.1. Market Estimation, 2013 – 2018

10.2.2.5.1.2. Market Forecast, 2019 – 2027

10.2.2.5.2. Europe

10.2.2.5.2.1. Market Estimation, 2013 – 2018

10.2.2.5.2.2. Market Forecast, 2019 – 2027

10.2.2.5.3. Asia Pacific

10.2.2.5.3.1. Market Estimation, 2013 – 2018

10.2.2.5.3.2. Market Forecast, 2019 – 2027

10.2.2.5.4. Middle East and Africa

10.2.2.5.4.1. Market Estimation, 2013 – 2018

10.2.2.5.4.2. Market Forecast, 2019 – 2027

10.2.2.5.5. Latin America

10.2.2.5.5.1. Market Estimation, 2013 – 2018

10.2.2.5.5.2. Market Forecast, 2019 – 2027

10.2.3. Capsule

10.2.3.1.  Definition

10.2.3.2.  Market Estimation and Penetration, 2013 – 2018

10.2.3.3.  Market Forecast, 2019 – 2027

10.2.3.4.  Compound Annual Growth Rate (CAGR)

10.2.3.5.  Regional Bifurcation

10.2.3.5.1. North America

10.2.3.5.1.1. Market Estimation, 2013 – 2018

10.2.3.5.1.2. Market Forecast, 2019 – 2027

10.2.3.5.2. Europe

10.2.3.5.2.1. Market Estimation, 2013 – 2018

10.2.3.5.2.2. Market Forecast, 2019 – 2027

10.2.3.5.3. Asia Pacific

10.2.3.5.3.1. Market Estimation, 2013 – 2018

10.2.3.5.3.2. Market Forecast, 2019 – 2027

10.2.3.5.4. Middle East and Africa

10.2.3.5.4.1. Market Estimation, 2013 – 2018

10.2.3.5.4.2. Market Forecast, 2019 – 2027

10.2.3.5.5. Latin America

10.2.3.5.5.1. Market Estimation, 2013 – 2018

10.2.3.5.5.2. Market Forecast, 2019 – 2027

10.2.4. Tablet

10.2.4.1.  Definition

10.2.4.2.  Market Estimation and Penetration, 2013 – 2018

10.2.4.3.  Market Forecast, 2019 – 2027

10.2.4.4.  Compound Annual Growth Rate (CAGR)

10.2.4.5.  Regional Bifurcation

10.2.4.5.1. North America

10.2.4.5.1.1. Market Estimation, 2013 – 2018

10.2.4.5.1.2. Market Forecast, 2019 – 2027

10.2.4.5.2. Europe

10.2.4.5.2.1. Market Estimation, 2013 – 2018

10.2.4.5.2.2. Market Forecast, 2019 – 2027

10.2.4.5.3. Asia Pacific

10.2.4.5.3.1. Market Estimation, 2013 – 2018

10.2.4.5.3.2. Market Forecast, 2019 – 2027

10.2.4.5.4. Middle East and Africa

10.2.4.5.4.1. Market Estimation, 2013 – 2018

10.2.4.5.4.2. Market Forecast, 2019 – 2027

10.2.4.5.5. Latin America

10.2.4.5.5.1. Market Estimation, 2013 – 2018

10.2.4.5.5.2. Market Forecast, 2019 – 2027

10.3. Key Segment for Channeling Investments

10.3.1. By Form

11. Global Cystic Fibrosis Therapeutics Market Analysis and Forecasts, 2019 – 2027

11.1. Overview

11.2. Global Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

11.2.1. Hospital Pharmacies

11.2.1.1.  Definition

11.2.1.2.  Market Estimation and Penetration, 2013 – 2018

11.2.1.3.  Market Forecast, 2019 – 2027

11.2.1.4.  Compound Annual Growth Rate (CAGR)

11.2.1.5.  Regional Bifurcation

11.2.1.5.1. North America

11.2.1.5.1.1. Market Estimation, 2013 – 2018

11.2.1.5.1.2. Market Forecast, 2019 – 2027

11.2.1.5.2. Europe

11.2.1.5.2.1. Market Estimation, 2013 – 2018

11.2.1.5.2.2. Market Forecast, 2019 – 2027

11.2.1.5.3. Asia Pacific

11.2.1.5.3.1. Market Estimation, 2013 – 2018

11.2.1.5.3.2. Market Forecast, 2019 – 2027

11.2.1.5.4. Middle East and Africa

11.2.1.5.4.1. Market Estimation, 2013 – 2018

11.2.1.5.4.2. Market Forecast, 2019 – 2027

11.2.1.5.5. Latin America

11.2.1.5.5.1. Market Estimation, 2013 – 2018

11.2.1.5.5.2. Market Forecast, 2019 – 2027

11.2.2. Retail Pharmacies

11.2.2.1.  Definition

11.2.2.2.  Market Estimation and Penetration, 2013 – 2018

11.2.2.3.  Market Forecast, 2019 – 2027

11.2.2.4.  Compound Annual Growth Rate (CAGR)

11.2.2.5.  Regional Bifurcation

11.2.2.5.1. North America

11.2.2.5.1.1. Market Estimation, 2013 – 2018

11.2.2.5.1.2. Market Forecast, 2019 – 2027

11.2.2.5.2. Europe

11.2.2.5.2.1. Market Estimation, 2013 – 2018

11.2.2.5.2.2. Market Forecast, 2019 – 2027

11.2.2.5.3. Asia Pacific

11.2.2.5.3.1. Market Estimation, 2013 – 2018

11.2.2.5.3.2. Market Forecast, 2019 – 2027

11.2.2.5.4. Middle East and Africa

11.2.2.5.4.1. Market Estimation, 2013 – 2018

11.2.2.5.4.2. Market Forecast, 2019 – 2027

11.2.2.5.5. Latin America

11.2.2.5.5.1. Market Estimation, 2013 – 2018

11.2.2.5.5.2. Market Forecast, 2019 – 2027

11.2.3. Online Pharmacies

11.2.3.1.  Definition

11.2.3.2.  Market Estimation and Penetration, 2013 – 2018

11.2.3.3.  Market Forecast, 2019 – 2027

11.2.3.4.  Compound Annual Growth Rate (CAGR)

11.2.3.5.  Regional Bifurcation

11.2.3.5.1. North America

11.2.3.5.1.1. Market Estimation, 2013 – 2018

11.2.3.5.1.2. Market Forecast, 2019 – 2027

11.2.3.5.2. Europe

11.2.3.5.2.1. Market Estimation, 2013 – 2018

11.2.3.5.2.2. Market Forecast, 2019 – 2027

11.2.3.5.3. Asia Pacific

11.2.3.5.3.1. Market Estimation, 2013 – 2018

11.2.3.5.3.2. Market Forecast, 2019 – 2027

11.2.3.5.4. Middle East and Africa

11.2.3.5.4.1. Market Estimation, 2013 – 2018

11.2.3.5.4.2. Market Forecast, 2019 – 2027

11.2.3.5.5. Latin America

11.2.3.5.5.1. Market Estimation, 2013 – 2018

11.2.3.5.5.2. Market Forecast, 2019 – 2027

11.3. Key Segment for Channeling Investments

11.3.1. By Distribution Channel

12. North America Cystic Fibrosis Therapeutics Market Analysis and Forecasts, 2019 - 2027

12.1. Overview

12.1.1. North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn)

12.2. North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

12.2.1. CFTR Modulators

12.2.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

12.2.3. Antibiotics

12.2.4. Pancreatic Enzyme Replacement Therapy (PERT)

12.3. North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

12.3.1. Oral

12.3.2. Inhalation

12.4. North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

12.4.1. Powder

12.4.2. Liquid

12.4.3. Capsule

12.4.4. Tablet

12.5. North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

12.5.1. Hospital Pharmacies

12.5.2. Retail Pharmacies

12.5.3. Online Pharmacies

12.6. North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country

12.6.1. U.S

12.6.1.1.  U.S Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

12.6.1.1.1. CFTR Modulators

12.6.1.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

12.6.1.1.3. Antibiotics

12.6.1.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

12.6.1.2.  U.S Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

12.6.1.2.1. Oral

12.6.1.2.2. Inhalation

12.6.1.3.  U.S Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

12.6.1.3.1. Powder

12.6.1.3.2. Liquid

12.6.1.3.3. Capsule

12.6.1.3.4. Tablet

12.6.1.4.  U.S Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

12.6.1.4.1. Hospital Pharmacies

12.6.1.4.2. Retail Pharmacies

12.6.1.4.3. Online Pharmacies

12.6.2. Canada

12.6.2.1.  Canada Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

12.6.2.1.1. CFTR Modulators

12.6.2.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

12.6.2.1.3. Antibiotics

12.6.2.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

12.6.2.2.  Canada Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

12.6.2.2.1. Oral

12.6.2.2.2. Inhalation

12.6.2.3.  Canada Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

12.6.2.3.1. Powder

12.6.2.3.2. Liquid

12.6.2.3.3. Capsule

12.6.2.3.4. Tablet

12.6.2.4.  Canada Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

12.6.2.4.1. Hospital Pharmacies

12.6.2.4.2. Retail Pharmacies

12.6.2.4.3. Online Pharmacies

12.6.3. Mexico

12.6.3.1.  Mexico Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

12.6.3.1.1. CFTR Modulators

12.6.3.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

12.6.3.1.3. Antibiotics

12.6.3.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

12.6.3.2.  Mexico Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

12.6.3.2.1. Oral

12.6.3.2.2. Inhalation

12.6.3.3.  Mexico Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

12.6.3.3.1. Powder

12.6.3.3.2. Liquid

12.6.3.3.3. Capsule

12.6.3.3.4. Tablet

12.6.3.4.  Mexico Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

12.6.3.4.1. Hospital Pharmacies

12.6.3.4.2. Retail Pharmacies

12.6.3.4.3. Online Pharmacies

12.6.4. Rest of North America

12.6.4.1.  Rest of North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

12.6.4.1.1. CFTR Modulators

12.6.4.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

12.6.4.1.3. Antibiotics

12.6.4.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

12.6.4.2.  Rest of North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

12.6.4.2.1. Oral

12.6.4.2.2. Inhalation

12.6.4.3.  Rest of North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

12.6.4.3.1. Powder

12.6.4.3.2. Liquid

12.6.4.3.3. Capsule

12.6.4.3.4. Tablet

12.6.4.4.  Rest of North America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

12.6.4.4.1. Hospital Pharmacies

12.6.4.4.2. Retail Pharmacies

12.6.4.4.3. Online Pharmacies

12.7. Key Segment for Channeling Investments

12.7.1. By Country

12.7.2. By Drugs Class

12.7.3. By Route of Administration

12.7.4. By Form

12.7.5. By Distribution Channel

13. Europe Cystic Fibrosis Therapeutics Market Analysis and Forecasts, 2019 - 2027

13.1. Overview

13.1.1. Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn)

13.2. Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

13.2.1. CFTR Modulators

13.2.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

13.2.3. Antibiotics

13.2.4. Pancreatic Enzyme Replacement Therapy (PERT)

13.3. Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.3.1. Oral

13.3.2. Inhalation

13.4. Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

13.4.1. Powder

13.4.2. Liquid

13.4.3. Capsule

13.4.4. Tablet

13.5. Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

13.5.1. Hospital Pharmacies

13.5.2. Retail Pharmacies

13.5.3. Online Pharmacies

13.6. Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country

13.6.1. France

13.6.1.1.  France Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

13.6.1.1.1. CFTR Modulators

13.6.1.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

13.6.1.1.3. Antibiotics

13.6.1.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

13.6.1.2.  France Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.6.1.2.1. Oral

13.6.1.2.2. Inhalation

13.6.1.3.  France Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

13.6.1.3.1. Powder

13.6.1.3.2. Liquid

13.6.1.3.3. Capsule

13.6.1.3.4. Tablet

13.6.1.4.  France Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

13.6.1.4.1. Hospital Pharmacies

13.6.1.4.2. Retail Pharmacies

13.6.1.4.3. Online Pharmacies

13.6.2. The UK

13.6.2.1.  The UK Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

13.6.2.1.1. CFTR Modulators

13.6.2.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

13.6.2.1.3. Antibiotics

13.6.2.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

13.6.2.2.  The UK Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.6.2.2.1. Oral

13.6.2.2.2. Inhalation

13.6.2.3.  The UK Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

13.6.2.3.1. Powder

13.6.2.3.2. Liquid

13.6.2.3.3. Capsule

13.6.2.3.4. Tablet

13.6.2.4.  The UK Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

13.6.2.4.1. Hospital Pharmacies

13.6.2.4.2. Retail Pharmacies

13.6.2.4.3. Online Pharmacies

13.6.3. Spain

13.6.3.1.  Spain Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

13.6.3.1.1. CFTR Modulators

13.6.3.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

13.6.3.1.3. Antibiotics

13.6.3.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

13.6.3.2.  Spain Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.6.3.2.1. Oral

13.6.3.2.2. Inhalation

13.6.3.3.  Spain Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

13.6.3.3.1. Powder

13.6.3.3.2. Liquid

13.6.3.3.3. Capsule

13.6.3.3.4. Tablet

13.6.3.4.  Spain Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

13.6.3.4.1. Hospital Pharmacies

13.6.3.4.2. Retail Pharmacies

13.6.3.4.3. Online Pharmacies

13.6.4. Germany

13.6.4.1.  Germany Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

13.6.4.1.1. CFTR Modulators

13.6.4.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

13.6.4.1.3. Antibiotics

13.6.4.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

13.6.4.2.  Germany Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.6.4.2.1. Oral

13.6.4.2.2. Inhalation

13.6.4.3.  Germany Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

13.6.4.3.1. Powder

13.6.4.3.2. Liquid

13.6.4.3.3. Capsule

13.6.4.3.4. Tablet

13.6.4.4.  Germany Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

13.6.4.4.1. Hospital Pharmacies

13.6.4.4.2. Retail Pharmacies

13.6.4.4.3. Online Pharmacies

13.6.5. Italy

13.6.5.1.  Italy Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

13.6.5.1.1. CFTR Modulators

13.6.5.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

13.6.5.1.3. Antibiotics

13.6.5.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

13.6.5.2.  Italy Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.6.5.2.1. Oral

13.6.5.2.2. Inhalation

13.6.5.3.  Italy Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

13.6.5.3.1. Powder

13.6.5.3.2. Liquid

13.6.5.3.3. Capsule

13.6.5.3.4. Tablet

13.6.5.4.  Italy Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

13.6.5.4.1. Hospital Pharmacies

13.6.5.4.2. Retail Pharmacies

13.6.5.4.3. Online Pharmacies

13.6.6. Nordic Countries

13.6.6.1.  Nordic Countries Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

13.6.6.1.1. CFTR Modulators

13.6.6.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

13.6.6.1.3. Antibiotics

13.6.6.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

13.6.6.2.  Nordic Countries Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.6.6.2.1. Oral

13.6.6.2.2. Inhalation

13.6.6.3.  Nordic Countries Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

13.6.6.3.1. Powder

13.6.6.3.2. Liquid

13.6.6.3.3. Capsule

13.6.6.3.4. Tablet

13.6.6.4.  Nordic Countries Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

13.6.6.4.1. Hospital Pharmacies

13.6.6.4.2. Retail Pharmacies

13.6.6.4.3. Online Pharmacies

13.6.6.5.  Nordic Countries Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country

13.6.6.5.1. Denmark

13.6.6.5.2. Finland

13.6.6.5.3. Iceland

13.6.6.5.4. Sweden

13.6.6.5.5. Norway

13.6.7. Benelux Union

13.6.7.1.  Benelux Union Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

13.6.7.1.1. CFTR Modulators

13.6.7.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

13.6.7.1.3. Antibiotics

13.6.7.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

13.6.7.2.  Benelux Union Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.6.7.2.1. Oral

13.6.7.2.2. Inhalation

13.6.7.3.  Benelux Union Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

13.6.7.3.1. Powder

13.6.7.3.2. Liquid

13.6.7.3.3. Capsule

13.6.7.3.4. Tablet

13.6.7.4.  Benelux Union Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

13.6.7.4.1. Hospital Pharmacies

13.6.7.4.2. Retail Pharmacies

13.6.7.4.3. Online Pharmacies

13.6.7.5.  Benelux Union Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country

13.6.7.5.1. Belgium

13.6.7.5.2. The Netherlands

13.6.7.5.3. Luxembourg

13.6.8. Rest of Europe

13.6.8.1.  Rest of Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

13.6.8.1.1. CFTR Modulators

13.6.8.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

13.6.8.1.3. Antibiotics

13.6.8.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

13.6.8.2.  Rest of Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

13.6.8.2.1. Oral

13.6.8.2.2. Inhalation

13.6.8.3.  Rest of Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

13.6.8.3.1. Powder

13.6.8.3.2. Liquid

13.6.8.3.3. Capsule

13.6.8.3.4. Tablet

13.6.8.4.  Rest of Europe Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

13.6.8.4.1. Hospital Pharmacies

13.6.8.4.2. Retail Pharmacies

13.6.8.4.3. Online Pharmacies

13.7. Key Segment for Channeling Investments

13.7.1. By Country

13.7.2. By Drugs Class

13.7.3. By Route of Administration

13.7.4. By Form

13.7.5. By Distribution Channel

14. Asia Pacific Cystic Fibrosis Therapeutics Market Analysis and Forecasts, 2019 - 2027

14.1. Overview

14.1.1. Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn)

14.2. Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

14.2.1. CFTR Modulators

14.2.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

14.2.3. Antibiotics

14.2.4. Pancreatic Enzyme Replacement Therapy (PERT)

14.3. Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.3.1. Oral

14.3.2. Inhalation

14.4. Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

14.4.1. Powder

14.4.2. Liquid

14.4.3. Capsule

14.4.4. Tablet

14.5. Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

14.5.1. Hospital Pharmacies

14.5.2. Retail Pharmacies

14.5.3. Online Pharmacies

14.6. Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country

14.6.1. China

14.6.1.1.  China Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

14.6.1.1.1. CFTR Modulators

14.6.1.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

14.6.1.1.3. Antibiotics

14.6.1.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

14.6.1.2.  China Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.6.1.2.1. Oral

14.6.1.2.2. Inhalation

14.6.1.3.  China Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

14.6.1.3.1. Powder

14.6.1.3.2. Liquid

14.6.1.3.3. Capsule

14.6.1.3.4. Tablet

14.6.1.4.  China Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

14.6.1.4.1. Hospital Pharmacies

14.6.1.4.2. Retail Pharmacies

14.6.1.4.3. Online Pharmacies

14.6.2. Japan

14.6.2.1.  Japan Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

14.6.2.1.1. CFTR Modulators

14.6.2.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

14.6.2.1.3. Antibiotics

14.6.2.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

14.6.2.2.  Japan Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.6.2.2.1. Oral

14.6.2.2.2. Inhalation

14.6.2.3.  Japan Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

14.6.2.3.1. Powder

14.6.2.3.2. Liquid

14.6.2.3.3. Capsule

14.6.2.3.4. Tablet

14.6.2.4.  Japan Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

14.6.2.4.1. Hospital Pharmacies

14.6.2.4.2. Retail Pharmacies

14.6.2.4.3. Online Pharmacies

14.6.3. India

14.6.3.1.  India Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

14.6.3.1.1. CFTR Modulators

14.6.3.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

14.6.3.1.3. Antibiotics

14.6.3.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

14.6.3.2.  India Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.6.3.2.1. Oral

14.6.3.2.2. Inhalation

14.6.3.3.  India Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

14.6.3.3.1. Powder

14.6.3.3.2. Liquid

14.6.3.3.3. Capsule

14.6.3.3.4. Tablet

14.6.3.4.  India Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

14.6.3.4.1. Hospital Pharmacies

14.6.3.4.2. Retail Pharmacies

14.6.3.4.3. Online Pharmacies

14.6.4. New Zealand

14.6.4.1.  New Zealand Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

14.6.4.1.1. CFTR Modulators

14.6.4.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

14.6.4.1.3. Antibiotics

14.6.4.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

14.6.4.2.  New Zealand Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.6.4.2.1. Oral

14.6.4.2.2. Inhalation

14.6.4.3.  New Zealand Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

14.6.4.3.1. Powder

14.6.4.3.2. Liquid

14.6.4.3.3. Capsule

14.6.4.3.4. Tablet

14.6.4.4.  New Zealand Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

14.6.4.4.1. Hospital Pharmacies

14.6.4.4.2. Retail Pharmacies

14.6.4.4.3. Online Pharmacies

14.6.5. Australia

14.6.5.1.  Australia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

14.6.5.1.1. CFTR Modulators

14.6.5.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

14.6.5.1.3. Antibiotics

14.6.5.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

14.6.5.2.  Australia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.6.5.2.1. Oral

14.6.5.2.2. Inhalation

14.6.5.3.  Australia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

14.6.5.3.1. Powder

14.6.5.3.2. Liquid

14.6.5.3.3. Capsule

14.6.5.3.4. Tablet

14.6.5.4.  Australia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

14.6.5.4.1. Hospital Pharmacies

14.6.5.4.2. Retail Pharmacies

14.6.5.4.3. Online Pharmacies

14.6.6. South Korea

14.6.6.1.  South Korea Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

14.6.6.1.1. CFTR Modulators

14.6.6.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

14.6.6.1.3. Antibiotics

14.6.6.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

14.6.6.2.  South Korea Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.6.6.2.1. Oral

14.6.6.2.2. Inhalation

14.6.6.3.  South Korea Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

14.6.6.3.1. Powder

14.6.6.3.2. Liquid

14.6.6.3.3. Capsule

14.6.6.3.4. Tablet

14.6.6.4.  South Korea Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

14.6.6.4.1. Hospital Pharmacies

14.6.6.4.2. Retail Pharmacies

14.6.6.4.3. Online Pharmacies

14.6.7. Southeast Asia

14.6.7.1.  Southeast Asia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

14.6.7.1.1. CFTR Modulators

14.6.7.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

14.6.7.1.3. Antibiotics

14.6.7.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

14.6.7.2.  Southeast Asia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.6.7.2.1. Oral

14.6.7.2.2. Inhalation

14.6.7.3.  Southeast Asia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

14.6.7.3.1. Powder

14.6.7.3.2. Liquid

14.6.7.3.3. Capsule

14.6.7.3.4. Tablet

14.6.7.4.  Southeast Asia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

14.6.7.4.1. Hospital Pharmacies

14.6.7.4.2. Retail Pharmacies

14.6.7.4.3. Online Pharmacies

14.6.7.5.  Southeast Asia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country

14.6.7.5.1. Indonesia

14.6.7.5.2. Thailand

14.6.7.5.3. Malaysia

14.6.7.5.4. Singapore

14.6.7.5.5. Rest of Southeast Asia

14.6.8. Rest of Asia Pacific

14.6.8.1.  Rest of Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

14.6.8.1.1. CFTR Modulators

14.6.8.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

14.6.8.1.3. Antibiotics

14.6.8.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

14.6.8.2.  Rest of Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

14.6.8.2.1. Oral

14.6.8.2.2. Inhalation

14.6.8.3.  Rest of Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

14.6.8.3.1. Powder

14.6.8.3.2. Liquid

14.6.8.3.3. Capsule

14.6.8.3.4. Tablet

14.6.8.4.  Rest of Asia Pacific Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

14.6.8.4.1. Hospital Pharmacies

14.6.8.4.2. Retail Pharmacies

14.6.8.4.3. Online Pharmacies

14.7. Key Segment for Channeling Investments

14.7.1. By Country

14.7.2. By Drugs Class

14.7.3. By Route of Administration

14.7.4. By Form

14.7.5. By Distribution Channel

15. Middle East and Africa Cystic Fibrosis Therapeutics Market Analysis and Forecasts, 2019 - 2027

15.1. Overview

15.1.1. Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn)

15.2. Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

15.2.1. CFTR Modulators

15.2.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

15.2.3. Antibiotics

15.2.4. Pancreatic Enzyme Replacement Therapy (PERT)

15.3. Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.3.1. Oral

15.3.2. Inhalation

15.4. Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

15.4.1. Powder

15.4.2. Liquid

15.4.3. Capsule

15.4.4. Tablet

15.5. Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

15.5.1. Hospital Pharmacies

15.5.2. Retail Pharmacies

15.5.3. Online Pharmacies

15.6. Middle East and Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country

15.6.1. Saudi Arabia

15.6.1.1.  Saudi Arabia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

15.6.1.1.1. CFTR Modulators

15.6.1.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

15.6.1.1.3. Antibiotics

15.6.1.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

15.6.1.2.  Saudi Arabia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.6.1.2.1. Oral

15.6.1.2.2. Inhalation

15.6.1.3.  Saudi Arabia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

15.6.1.3.1. Powder

15.6.1.3.2. Liquid

15.6.1.3.3. Capsule

15.6.1.3.4. Tablet

15.6.1.4.  Saudi Arabia Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

15.6.1.4.1. Hospital Pharmacies

15.6.1.4.2. Retail Pharmacies

15.6.1.4.3. Online Pharmacies

15.6.2. UAE

15.6.2.1.  UAE Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

15.6.2.1.1. CFTR Modulators

15.6.2.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

15.6.2.1.3. Antibiotics

15.6.2.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

15.6.2.2.  UAE Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.6.2.2.1. Oral

15.6.2.2.2. Inhalation

15.6.2.3.  UAE Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

15.6.2.3.1. Powder

15.6.2.3.2. Liquid

15.6.2.3.3. Capsule

15.6.2.3.4. Tablet

15.6.2.4.  UAE Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

15.6.2.4.1. Hospital Pharmacies

15.6.2.4.2. Retail Pharmacies

15.6.2.4.3. Online Pharmacies

15.6.3. Egypt

15.6.3.1.  Egypt Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

15.6.3.1.1. CFTR Modulators

15.6.3.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

15.6.3.1.3. Antibiotics

15.6.3.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

15.6.3.2.  Egypt Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.6.3.2.1. Oral

15.6.3.2.2. Inhalation

15.6.3.3.  Egypt Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

15.6.3.3.1. Powder

15.6.3.3.2. Liquid

15.6.3.3.3. Capsule

15.6.3.3.4. Tablet

15.6.3.4.  Egypt Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

15.6.3.4.1. Hospital Pharmacies

15.6.3.4.2. Retail Pharmacies

15.6.3.4.3. Online Pharmacies

15.6.4. Kuwait

15.6.4.1.  Kuwait Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

15.6.4.1.1. CFTR Modulators

15.6.4.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

15.6.4.1.3. Antibiotics

15.6.4.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

15.6.4.2.  Kuwait Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.6.4.2.1. Oral

15.6.4.2.2. Inhalation

15.6.4.3.  Kuwait Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

15.6.4.3.1. Powder

15.6.4.3.2. Liquid

15.6.4.3.3. Capsule

15.6.4.3.4. Tablet

15.6.4.4.  Kuwait Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

15.6.4.4.1. Hospital Pharmacies

15.6.4.4.2. Retail Pharmacies

15.6.4.4.3. Online Pharmacies

15.6.5. South Africa

15.6.5.1.  South Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

15.6.5.1.1. CFTR Modulators

15.6.5.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

15.6.5.1.3. Antibiotics

15.6.5.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

15.6.5.2.  South Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.6.5.2.1. Oral

15.6.5.2.2. Inhalation

15.6.5.3.  South Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

15.6.5.3.1. Powder

15.6.5.3.2. Liquid

15.6.5.3.3. Capsule

15.6.5.3.4. Tablet

15.6.5.4.  South Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

15.6.5.4.1. Hospital Pharmacies

15.6.5.4.2. Retail Pharmacies

15.6.5.4.3. Online Pharmacies

15.6.6. Rest of Middle East & Africa

15.6.6.1.  Rest of Middle East & Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

15.6.6.1.1. CFTR Modulators

15.6.6.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

15.6.6.1.3. Antibiotics

15.6.6.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

15.6.6.2.  Rest of Middle East & Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

15.6.6.2.1. Oral

15.6.6.2.2. Inhalation

15.6.6.3.  Rest of Middle East & Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

15.6.6.3.1. Powder

15.6.6.3.2. Liquid

15.6.6.3.3. Capsule

15.6.6.3.4. Tablet

15.6.6.4.  Rest of Middle East & Africa Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

15.6.6.4.1. Hospital Pharmacies

15.6.6.4.2. Retail Pharmacies

15.6.6.4.3. Online Pharmacies

15.7. Key Segment for Channeling Investments

15.7.1. By Country

15.7.2. By Drugs Class

15.7.3. By Route of Administration

15.7.4. By Form

15.7.5. By Distribution Channel

16. Latin America Cystic Fibrosis Therapeutics Market Analysis and Forecasts, 2019 - 2027

16.1. Overview

16.1.1. Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn)

16.2. Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

16.2.1. CFTR Modulators

16.2.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

16.2.3. Antibiotics

16.2.4. Pancreatic Enzyme Replacement Therapy (PERT)

16.3. Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

16.3.1. Oral

16.3.2. Inhalation

16.4. Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

16.4.1. Powder

16.4.2. Liquid

16.4.3. Capsule

16.4.4. Tablet

16.5. Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

16.5.1. Hospital Pharmacies

16.5.2. Retail Pharmacies

16.5.3. Online Pharmacies

16.6. Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Country

16.6.1. Brazil

16.6.1.1.  Brazil Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

16.6.1.1.1. CFTR Modulators

16.6.1.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

16.6.1.1.3. Antibiotics

16.6.1.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

16.6.1.2.  Brazil Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

16.6.1.2.1. Oral

16.6.1.2.2. Inhalation

16.6.1.3.  Brazil Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

16.6.1.3.1. Powder

16.6.1.3.2. Liquid

16.6.1.3.3. Capsule

16.6.1.3.4. Tablet

16.6.1.4.  Brazil Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

16.6.1.4.1. Hospital Pharmacies

16.6.1.4.2. Retail Pharmacies

16.6.1.4.3. Online Pharmacies

16.6.2. Argentina

16.6.2.1.  Argentina Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

16.6.2.1.1. CFTR Modulators

16.6.2.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

16.6.2.1.3. Antibiotics

16.6.2.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

16.6.2.2.  Argentina Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

16.6.2.2.1. Oral

16.6.2.2.2. Inhalation

16.6.2.3.  Argentina Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

16.6.2.3.1. Powder

16.6.2.3.2. Liquid

16.6.2.3.3. Capsule

16.6.2.3.4. Tablet

16.6.2.4.  Argentina Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

16.6.2.4.1. Hospital Pharmacies

16.6.2.4.2. Retail Pharmacies

16.6.2.4.3. Online Pharmacies

16.6.3. Rest of Latin America

16.6.3.1.  Rest of Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Drugs Class

16.6.3.1.1. CFTR Modulators

16.6.3.1.2. Mucolytics (Mucoactive Drugs) and Bronchodilators

16.6.3.1.3. Antibiotics

16.6.3.1.4. Pancreatic Enzyme Replacement Therapy (PERT)

16.6.3.2.  Rest of Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Route of Administration

16.6.3.2.1. Oral

16.6.3.2.2. Inhalation

16.6.3.3.  Rest of Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Form

16.6.3.3.1. Powder

16.6.3.3.2. Liquid

16.6.3.3.3. Capsule

16.6.3.3.4. Tablet

16.6.3.4.  Rest of Latin America Cystic Fibrosis Therapeutics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel

16.6.3.4.1. Hospital Pharmacies

16.6.3.4.2. Retail Pharmacies

16.6.3.4.3. Online Pharmacies

16.7. Key Segment for Channeling Investments

16.7.1. By Country

16.7.2. By Drugs Class

16.7.3. By Route of Administration

16.7.4. By Form

16.7.5. By Distribution Channel

17. Competitive Benchmarking

17.1. Brand Benchmarking

17.2. Market Share Analysis, 2018

17.3. Global Presence and Growth Strategies

17.3.1. Mergers and Acquisitions

17.3.2. Product Launches

17.3.3. Investments Trends

17.3.4. R&D Initiatives

18. Player Profiles

18.1. AbbVie Inc.

18.1.1. Company Details

18.1.2. Company Overview

18.1.3. Product Offerings

18.1.4. Key Developments

18.1.5. Financial Analysis

18.1.6. SWOT Analysis

18.1.7. Business Strategies

18.2. Aradigm Corporation.

18.2.1. Company Details

18.2.2. Company Overview

18.2.3. Product Offerings

18.2.4. Key Developments

18.2.5. Financial Analysis

18.2.6. SWOT Analysis

18.2.7. Business Strategies

18.3. CHIESI Farmaceutici S.p.A.

18.3.1. Company Details

18.3.2. Company Overview

18.3.3. Product Offerings

18.3.4. Key Developments

18.3.5. Financial Analysis

18.3.6. SWOT Analysis

18.3.7. Business Strategies

18.4. Celtaxsys Aus Pty Limited

18.4.1. Company Details

18.4.2. Company Overview

18.4.3. Product Offerings

18.4.4. Key Developments

18.4.5. Financial Analysis

18.4.6. SWOT Analysis

18.4.7. Business Strategies

18.5. Demegen, Inc.

18.5.1. Company Details

18.5.2. Company Overview

18.5.3. Product Offerings

18.5.4. Key Developments

18.5.5. Financial Analysis

18.5.6. SWOT Analysis

18.5.7. Business Strategies

18.6. Digestive Care, Inc.

18.6.1. Company Details

18.6.2. Company Overview

18.6.3. Product Offerings

18.6.4. Key Developments

18.6.5. Financial Analysis

18.6.6. SWOT Analysis

18.6.7. Business Strategies

18.7. F. Hoffmann

18.7.1. Company Details

18.7.2. Company Overview

18.7.3. Product Offerings

18.7.4. Key Developments

18.7.5. Financial Analysis

18.7.6. SWOT Analysis

18.7.7. Business Strategies

18.8. Gilead Sciences, Inc.

18.8.1. Company Details

18.8.2. Company Overview

18.8.3. Product Offerings

18.8.4. Key Developments

18.8.5. Financial Analysis

18.8.6. SWOT Analysis

18.8.7. Business Strategies

18.9. Grifols, S.A.

18.9.1. Company Details

18.9.2. Company Overview

18.9.3. Product Offerings

18.9.4. Key Developments

18.9.5. Financial Analysis

18.9.6. SWOT Analysis

18.9.7. Business Strategies

18.10. Mylan N.V.

18.10.1. Company Details

18.10.2. Company Overview

18.10.3. Product Offerings

18.10.4. Key Developments

18.10.5. Financial Analysis

18.10.6. SWOT Analysis

18.10.7. Business Strategies

18.11. Novartis AG

18.11.1. Company Details

18.11.2. Company Overview

18.11.3. Product Offerings

18.11.4. Key Developments

18.11.5. Financial Analysis

18.11.6. SWOT Analysis

18.11.7. Business Strategies

18.12. PTC Therapeutics

18.12.1. Company Details

18.12.2. Company Overview

18.12.3. Product Offerings

18.12.4. Key Developments

18.12.5. Financial Analysis

18.12.6. SWOT Analysis

18.12.7. Business Strategies

18.13. Pharmaxis Ltd

18.13.1. Company Details

18.13.2. Company Overview

18.13.3. Product Offerings

18.13.4. Key Developments

18.13.5. Financial Analysis

18.13.6. SWOT Analysis

18.13.7. Business Strategies

18.14. Polydex Pharmaceuticals Limited

18.14.1. Company Details

18.14.2. Company Overview

18.14.3. Product Offerings

18.14.4. Key Developments

18.14.5. Financial Analysis

18.14.6. SWOT Analysis

18.14.7. Business Strategies

18.15. Questex LLC

18.15.1. Company Details

18.15.2. Company Overview

18.15.3. Product Offerings

18.15.4. Key Developments

18.15.5. Financial Analysis

18.15.6. SWOT Analysis

18.15.7. Business Strategies

18.16. Vertex Pharmaceuticals Incorporated

18.16.1. Company Details

18.16.2. Company Overview

18.16.3. Product Offerings

18.16.4. Key Developments

18.16.5. Financial Analysis

18.16.6. SWOT Analysis

18.16.7. Business Strategies

19. Key Findings

 

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com